Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 8;32(8):492.
doi: 10.1007/s00520-024-08702-0.

Cardiac safety of ribociclib evaluated with 24-hour rhythm Holter electrocardiogram

Ayse Irem Yasin  1 , Mahmut Uluganyan  2 , Zehra Sucuoglu Isleyen  3 , Atakan Topcu  3 , Abdallah Tm Shbair  3 , Melih Simsek  3 , Mehmet Besiroglu  3 , Yeliz Emine Ersoy  4 , Hacı Mehmet Türk  3 , Mesut Seker  3
Affiliations

Cardiac safety of ribociclib evaluated with 24-hour rhythm Holter electrocardiogram

Ayse Irem Yasin et al. Support Care Cancer. .

Abstract

Objective: We aimed to evaluate cardiac safety profile of ribociclib with 24-h rhythm Holter ECG.

Material and method: Forty-two female metastatic breast cancer patients were included in the study. Rhythm Holter ECG was performed before starting treatment with ribociclib and after 3 months of the treatment initiation.

Results: The mean age of the patients was 56.36 ± 12.73. 52.4% (n = 22) of the patients were using ribociclib in combination with fulvestrant and 47.6% (n = 20) with aromatase inhibitors. None of the patients developed cardiotoxicity. When the rhythm Holter results before and in third month of the treatment were compared, there was no statistically significant difference.

Conclusion: This is the first study evaluating effects of ribociclib treatment on cardiac rhythm with Holter ECG. The findings suggested ribociclib has a low risk of causing early cardiotoxicity.

Keywords: Cardiotoxicity; Holter ECG; Hormon-positive breast cancer; Ribociclib.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Harbeck N, Penault-Llorca F, Cortes J et al (2019) Breast cancer. Nat Rev Dis Prim 5(1):66 10.1038/s41572-019-0111-2 - DOI - PubMed
    1. Jerzak KJ, Bouganim N, Brezden-Masley C et al (2023) HR+/HER2-advanced breast cancer treatment in the first-line setting: Expert Review. Curr Oncol 30(6):5425–5447 10.3390/curroncol30060411 - DOI - PMC - PubMed
    1. Cardoso F, Paluch-Shimon S, Senkus E et al (2020) 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 31(12):1623–1649 10.1016/j.annonc.2020.09.010 - DOI - PMC - PubMed
    1. Johnston S, Martin M, Di Leo A et al (2019) MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer 5:5 10.1038/s41523-018-0097-z - DOI - PMC - PubMed
    1. Hortobagyi GN, Stemmer SM, Burris HA et al (2018) Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 29(7):1541–1547 10.1093/annonc/mdy155 - DOI - PubMed

MeSH terms

LinkOut - more resources